Procept Biorobotics Corp (PRCT) has reported better-than-expected financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) of $-0.38 surpassed Wall Street's consensus estimate of $-0.42 by $0.04. Revenue for the quarter matched expectations at $0.1 billion.
The announcement highlights the company's operational performance, suggesting stronger business fundamentals. Procept Biorobotics is a commercial-stage surgical robotics firm based in San Jose, California, focused on developing transformative solutions in urology. Its flagship product, the AQUABEAM Robotic System, is designed for minimally invasive urologic surgery, particularly in treating benign prostatic hyperplasia (BPH).
The firm plans to host an earnings conference call after market close to discuss these results and provide further insights into its business performance.
Investors may find it beneficial to review the full earnings release and listen to management commentary for a comprehensive understanding of the quarter's performance and future outlook. Procept Biorobotics is scheduled to report its next earnings on August 3, 2026, with an EPS estimate of $-0.2584 and revenue expectations of $0.1 billion.